Comparison · NCT02623972-sae
Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: serious adverse events. Trial comparisons, record NCT02623972-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02623972-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.313 | 0.142 | 0.556 | wilson | |
| Risk in group 2 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk difference, group 1 minus group 2 | 0.146 | -0.286 | 0.425 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.88 | 0.272 | 12.9 | log | |
| Odds ratio, group 1 over group 2 | 2.27 | 0.208 | 24.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm A: Eribulin followed by AC than on Arm B: AC followed by Eribulin | 6.86 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: Eribulin followed by AC | * Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~* Two research breast biopsies~* Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~* Cyclophosphamide via iv a predetermined dosage and schedule per cycle~* Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~* Radiation Therapy~* Endocrine Therapy (if applicable)~* Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans~Eribulin: administered IV for 4 cycles~Adriamycin: administered IV with cyclophosphamide for 4 cycles~Cyclophosphamide: administered IV with adriamycin for 4 cycles | 5 | 16 | EG000 |
| Group 2 | Arm B: AC followed by Eribulin | * Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~* Cyclophosphamide via iv a predetermined dosage and schedule per cycle~* Two research breast biopsies~* Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~* Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~* Radiation Therapy~* Endocrine Therapy (if applicable)~* Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans~Eribulin: administered IV for 4 cycles~Adriamycin: administered IV with cyclophosphamide for 4 cycles~Cyclophosphamide: administered IV with adriamycin for 4 cycles | 1 | 6 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-Cause Mortality measurement is anticipated to last for at least 5 years. It is assessed every cycle for 8 cycles during treatment. After protocol therapy, every 3 months for 1 year, then every 6 months for 4 years, then annually until death. Adverse events(SAEs and OAEs) are assessed every cycle for 8 cycles. After protocol therapy, assessed approximately 4 weeks following completion of therapy. The median(range) number of competed cycles of therapy was 8(7-8). As such up to 24 weeks.
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
- NCT number
- NCT02623972
- Phases
- PHASE2
- Conditions
- Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- Eribulin, Adriamycin, Cyclophosphamide
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2022-12-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02623972?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02623972-sae